Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.

Studied

Randomized trial comparing oral semaglutide with placebo alongside standard care for cardiovascular death, nonfatal heart attack or stroke.

Who / model

9650 adults aged 50 or older with type 2 diabetes and cardiovascular disease, chronic kidney disease or both; median follow-up was 49.5 months.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The primary cardiovascular outcome occurred in 12.0% versus 13.8%. Confirmatory secondary outcomes, including kidney disease events, did not differ significantly. Serious adverse events occurred in 47.9% versus 50.3%, and digestive disorders in 5.0% versus 4.4%.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary